Beltrán-Pérez J, Delgado-Picolomini A, Amador-Martínez AC, Téliz-Meneses MA, Barrientos-Priego Ai-Lan H, Reyes-Carrasco J

Language: Spanish
References: 23
Page: 132-139
PDF size: 544.02 Kb.

ABSTRACT

Introduction: Paragangliomas are tumors that originate in the nerve fibers of almost any sympathetic or parasympathetic chain in the body. There are different grades or types of metabolic activity and metastatic disease is uncommon.
Objective: The purpose of presenting this case is to point to the importance of a diagnostic approach using several imaging methods in the clinical context of a patient with sympathetic symptoms, and the accurate location of metastatic disease; and to show why it is so important to recognize the metabolic pattern for differential diagnoses of this disease.
Material and Methods: We report the case of a 41-year-old female patient who had signs and symptoms of the sympathetic nervous system associated to a history of removal of a carotid glomus tumor during her adolescence. Imaging studies were performed including PET and lymph node biopsy.
Results: Once pathologic and imaging studies were performed, especially with the use of 68Ga-DOTATOC as a radiotracer, an accurate diagnosis of the disease was reached.
Discussion: Nuclear medicine evaluation is crucial, and genetic diagnosis is necessary for specific clinical scenarios. The literature previously described that there are places of high altitude (such as Mexico City) associated with an increased prevalence of paragangliomas of the carotid glomus.
Conclusion: This case shows an adequate use of Radiological resources, especially from Nuclear Medicine, for the localization of the tumor and metastatic disease, with diagnostic and therapeutic purpose.

REFERENCES

1. Cobos González E, Aragón López JA, Soria Céspedes DR, de la Rosa Abaroa MA, Martínez de la Vega Celorio A, Granados Gracia M, et al. Malignant paraganglioma (multiple, multicentric and metastasic) in a female patient with family history of paraganglioma. Cir Esp. 2015;93:127-32.

2. Marti A. Metastasis paraganglioma: image with 18 F-flurodesoxiglucosepositron emission tomography. Rev Colomb Cancerol. 2013;17:162-5.

3. Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocrine-Related Cancer. 2011;18:253-76.

4. Gabiño B, Lazos M, Chávez L, Arrecillas M. Paragangliomas, estudio clínico patológico de 105 casos del Hospital General de México. Rev Med Hosp Gen Mex 2011;74:61-7

5. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210-6.

6. Boedeker CC, Neumann HP, Maier W, Bausch B, Schipper J, Ridder GJ. Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg. 2007;137:126-9.

7. Kuroiwa T, Kajimoto Y, Ohta T, Tsutsumi A. Symptomatic hypertrophic pacchionian granulation mimicking bone tumor: case report. Neurosurgery. 1996;39:860-6.

8. Bastug D, Ortiz O, Schochet SS. Hemangiomas in the calvaria: imaging findings. AJR Am J Roentgenol. 1995;164:683-7.

9. Amaral L, Chiurciu M, Almeida JR, Ferreira NF, Mendonça R, Lima SS. MR imaging for evaluation of lesions of the cranial vault: a pictorial essay. Arq Neuropsiquiatr. 2003;61:521-32.

10. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-66.

11. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002;108:132-9.

12. Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775-83.

13. Cerecer-Gil NY, Figuera LE, Llamas FJ, Lara M, Escamilla JG, Ramos R, et al. Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma. Clin Cancer Res. 2010;16:4148-54.

14. Kantorovich V, King KS, Pacak K. SDH-related pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2010;24:415-24.

15. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol. 2002;179:559-68.

16. Lee KY, Oh YW, Noh HJ, Lee YJ, Yong HS, Kang EY, et al. Extraadrenal paragangliomas of the body: imaging features. AJR Am J Roentgenol. 2006;187:492-504.

17. Timmers HJLM, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700-8.

18. Baez JC, Jagannathan JP, Krajewski K, O’Regan K, Zukotynski K, Kulke M, et al. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012;12:153-62.

19. Bustillo A, Telischi F, Weed D, Civantos F, Angeli S, Serafini A, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114:434-40.

20. Zografos GN, Vasiliadis G, Farfaras AN, Aggeli C, Digalakis M. Laparoscopic surgery for malignant adrenal tumors. JSLS. 2009;13:196-202.

21. He J, Makey D, Fojo T, Adams KT, Havekes B, Eisenhofer G, et al. Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine. 2009;36:189-93.

22. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-6.

23. Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. Falsenegative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012;19:83-93.